Discover the latest from PeriPharm – from new collaborations and scientific contributions to insights shaping market access.
The joint article by PeriPharm and Duchesnay, published in the Journal of Obstetrics and Gynaecology Canada, reveals significant gaps in access to women's health innovations…
This report conducted through our PROxy Network, an innovative research platform conducting real-world evidence studies through the collection of patient-reported outcomes (PROs), is a cross-sectional…
A joint study by Duchesnay and PeriPharm exposes critical gaps in access to innovative women's health products in Canada
Exactis Innovation and PeriPharm Forge Strategic Collaboration to Advance Real-World Evidence Studies
Generation of real-world evidence to better inform decision-making. This innovative PRO platform allows conducting real-world evidence studies in a timely manner.
PeriPharm is proud to be a platinum sponsor at the CADTH 2023 Symposium to be held in Ottawa from May 16 to 18.
A study evaluating, from a Canadian perspective, the impact of fixed-duration targeted therapies on the economic burden of chronic lymphocytic leukemia. Impact of Fixed-Duration Oral…
A study evaluating, from a Canadian perspective, the economic impact of venetoclax in combination with azacitidine for the treatment of patients with acute myeloid leukemia.…
PeriPharm is proud to attend and present some collaborations at the ISPOR Europe 2021 virtual conference which will be held from November 30 to December…
PeriPharm is proud to attend and present some collaborations at the ISPOR 2021 virtual conference held in May 2021.
PeriPharm is proud to attend and present some collaborations at the Association of Medical Microbiology and Infectious Disease Canada (AMMI Canada) 2021 annual virtual conference…
Presenting an impactful pan-Canadian collaboration in the treatment of CLL: Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada
